Related Experiment Video
Updated: Jan 1, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Development and characterization of CD73-siRNA-loaded nanoemulsion: effect on C6 glioma cells and primary astrocytes
Fernanda C Teixeira1, Fernanda Bruxel2, Juliana H Azambuja1,3
1Programa de Pós-Graduação em Bioquímica e Bioprospecção, Centro de Ciências Químicas, Farmacêuticas e de Alimentos, UFPEL, Pelotas, Brazil.
Abstract:
Introduction: Glioblastoma (GB) is the most common malignant brain tumor and is characterized by high invasiveness, poor prognosis, and limited therapeutic options. Silencing gene expression, through the use of small interfering RNA (siRNA), has been proposed as an alternative to conventional cancer therapy. Here, we evaluated the potential of CD73 as a new therapeutic target, since it is overexpressed in solid tumors and has emerged as a promising target to control GB progression.Methods: A cationic nanoemulsion (NE) as an intravenous siRNA-CD73 delivery system was developed and its effect on C6 glioma cell viability was determined.Results: The nanostructured system was effective in complexing oligonucleotides for delivery to target cells. In addition, we observed that the NE-siRNA-CD73 complex was effective in reducing CD73 protein levels and AMPase activity, which were related to decreased C6 glioma cell viability.Conclusions: These findings indicate the potential of siRNA-CD73-loaded cationic NE as a therapeutic alternative for glioma treatment.
Insights
Small interfering RNA (siRNA) targeting CD73, delivered via cationic nanoemulsions, effectively reduced glioma cell viability. This novel approach shows promise for glioblastoma treatment.
Area of Science:
- Oncology
- Nanomedicine
- Molecular Biology
Background:
- Glioblastoma (GB) is an aggressive brain tumor with poor prognosis and limited treatment options.
- Gene silencing using small interfering RNA (siRNA) offers a potential therapeutic strategy.
- CD73 is overexpressed in solid tumors, including glioblastoma, making it a potential therapeutic target.
Purpose of the Study:
- To evaluate CD73 as a therapeutic target for glioblastoma.
- To develop and assess a cationic nanoemulsion (NE) for intravenous delivery of siRNA targeting CD73 (siRNA-CD73).
Main Methods:
- Development of a cationic nanoemulsion (NE) for siRNA-CD73 delivery.
- Assessment of the NE-siRNA-CD73 complex's ability to complex oligonucleotides.
- Determination of the effect of NE-siRNA-CD73 on C6 glioma cell viability, CD73 protein levels, and AMPase activity.
Main Results:
- The cationic nanoemulsion effectively complexed siRNA for cellular delivery.
- NE-siRNA-CD73 significantly reduced CD73 protein levels and AMPase activity in C6 glioma cells.
- This reduction in CD73 was associated with decreased glioma cell viability.
Conclusions:
- siRNA-CD73-loaded cationic nanoemulsions demonstrate potential as a therapeutic alternative for glioma treatment.
- Targeting CD73 via siRNA delivery systems presents a promising strategy for glioblastoma therapy.
More Related Videos
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
12:25Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry
Published on: January 7, 2014